Thank you for Subscribing to Med Tech Business Review Weekly Brief
Medtech Business Review | Thursday, April 27, 2023
CROs and clinical service providers are merging and acquiring, raising questions about sustainability.
FREMONT, CA: Companies choose M&As over developing the same products domestically for various reasons, including increased size, regional growth, lower prices, and operational savings. Healthcare infrastructure may be a focal area for businesses seeking an M&A since having more control over it is crucial for fostering resilience. Clinical trials and active pharmaceutical ingredients share certain similarities and access to APIs is crucial to the efficiency of clinical studies. As a result, this affects just a few things since it can quicken regulatory clearance while simultaneously having a commercial driver component. Another factor contributing to the rise in M&A activity among CROs is the desire of some larger firms to acquire smaller rivals or start-ups, particularly in fields like patient recruitment, patient monitoring, and digital outcome measure tracking in clinical trials. Smaller software start-ups may frequently address extremely particular difficulties in clinical trial implementation because they concentrate on operational pain points.
The database of GlobalData indicates a surge in CRO M&As in 2021. Due to the disruption of several studies during the epidemic, CROs have had issues. But as governments and pharmaceutical companies try to support investments in novel therapies, demand for CRO services has increased.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Future of CRO: Regarding the present M&A and consolidation activities, there are many benefits and drawbacks. Industry participants anticipate that M&A activity and industry consolidation will continue for the foreseeable future. With rising R&D spending, venture capital financing, and outsourcing practices within the industry, the life sciences sector will continue to be the primary driver of the CRO sector. The CRO sector has to keep growing by using the bought model rather than constructing one. In the years to come, the continuing M&A activity and consolidation will likely continue, creating a new environment for CROs. The CRO industry is likely to be fragmented, with a small number of major players and many smaller ones that are either highly specialized in a particular drug class or disease or that provide specialized services or atomized clinical services like patient recruitment, feasibility testing, planning, data management, and so forth. On the other hand, this continual consolidation may be a successful tactic in the long run.
Challenges: When going through an M&A process, several issues might obstruct development and provide a variety of hazards for clinical trial sponsors. These dangers include, among others, conflicting work cultures, shifting business dynamics brought on by the CRO's restructuring, and services provided by the two CROs that overlap. Clinical trials, drug development, and the pharmaceutical sector have historically been characterized by long-term wagers, which do not always mesh well with M&As, when realizing immediate investment returns may be necessary. Some start-ups in the medical industry may find it difficult to obtain a lot of funding since the returns on investments might take a while to manifest because clinical research is an expensive process, and not all products make it to market.
Digitizing: For certain sponsors and pharmaceutical firms, consolidation might be challenging. However, it can still present opportunities, particularly where machine learning, automated software, and data are the main concerns. Rich, structured data may be used algorithmically in almost unlimited ways, including to perform synthetic trials, develop novel treatments, and enhance patient outcomes. The same data's use cases and the machine that uses it, like AI, and machine learning, may be repeatedly reused in other business models.
More in News